succinylcholine (anectine) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Succinylcholine also known as suxamethonium is a quaternary skeletal muscle relaxant usually used in the form of its halogen salt. It is is indicated under brand name anectine as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Succinylcholine activates the muscle-type nicotinic acetylcholine receptor followed by desensitization. Succinylcholine does not inhibit the presynaptic alpha3beta2 autoreceptor at clinically relevant concentrations, that provides a possible mechanistic explanation for the typical lack of tetanic fade in succinylcholine-induced neuromuscular blockade. Finally, was explored, that cardiovascular side effects (e.g., tachyarrhythmias) of succinylcholine were not mediated via direct activation of the autonomic ganglionic alpha3beta4 subtype because succinylcholine didn’t not activate the neuronal nicotinic acetylcholine receptor (nAChR) subtypes.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$8.9670 - $10.2512
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(n,n,n-trimethylethanaminium) | anectine | dicholine succinate | quelicin | quelicin preservative free | sc411 | sch 39641 | sch 697243 | scoline | succinic acid dicholine diester | succinic acid, diester with choline | succinocholine | succinoylcholine | succinylbischoline | succinylcholine | succinylcholine chloride | succinyldicholine | sucostrin | suxamethone | suxamethonium | suxamethonium chloride

Organizations (65)

Research & Development (40)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (25)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (1)


 

Muscle Relaxation (approved 1952)

Experimental Indications - Clinical Trial Phases 1-4 (24)


 

Anemia, Sickle Cell (Phase 3)

Anesthesia (Phase 4)

Anesthesia, General (Phase 3)

Bradycardia (Phase 2)

Cesarean Section (Phase 4)

Coma (Phase 4)

Conjunctivitis (Phase 3)

Depression (Phase 4)

Depressive Disorder, Major (Phase 4)

Hypersensitivity (Phase 3)

Intubation (Phase 4)

Intubation, Intratracheal (Phase 4)

Muscle Relaxants, Central (Phase 4)

Myalgia (Phase 3)

Neuromuscular Blockade (Phase 4)

Postoperative Complications (Phase 4)

Pregnancy (Phase 4)

Rapid Sequence Induction and Intubation (Phase 4)

Respiratory Distress Syndrome (Phase 4)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Shock (Phase 4)

Stroke (Phase 3)

Traumatology (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 42
  • # of Trial Organizations: 40

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue